Found 13 clinical trials
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
Lung cancer remains the most lethal malignancy in both sexes around the world. It is estimated that lung cancer caused 234,030 deaths in the United States in 2016, accounting for 28% of all cancer-related deaths. In 2012 alone, a total of 6,697 deaths from lung cancer were registered in Mexico; …
- 0 views
- 18 Feb, 2021
- 1 location
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An observational study
-
For all genders
-
Oncology
-
Currently Recruiting
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
receiving alectinib, ceritinib, lorlatinib, or other ALK inhibitors that may become available during study treatment.
- 15 views
- 25 Jan, 2021
- 1 location
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An observational study
-
For all genders
-
Oncology
-
Currently Recruiting
Study of Plasma NGS for Assessment Characterization Evaluation of Patients With ALK Resistance
developed drug resistance. This research study is for lung cancer patients with ALK-positive lung cancer who had been on a newer ALK targeted treatment (such as ceritinib, alectinib, brigatinib, or
- 0 views
- 25 Jan, 2021
- 1
- 2